ABOUT THE PROGRAM

The HIV Prevention Certified Provider Program is an online, self-paced CME curriculum composed of five courses in HIV prevention detailing the pertinent clinical and practice information that clinicians need to effectively employ HIV prevention interventions. Upon successful completion of this program, participants earn a certificate recognizing their designation as an HIV Prevention Certified Provider HIV PCP and receive listing in​ national online directory of HIV PCPs. The curriculum is updated annually and more frequently as needed, based on approval of new biomedical interventions and release of evidence-based practices.
 

THE NEED FOR AN HIV PCP

The 2019 Ending the HIV Epidemic: A Plan for America highlights increased HIV prevention efforts, including the need for more providers to prescribe pre-exposure prophylaxis (PrEP) and support clients with HIV in becoming virally suppressed. The HIV PCP program prepares and educates primary care providers, infectious disease specialists, internists, nurses, pharmacists, and other clinicians to deliver effective, comprehensive, culturally competent HIV prevention interventions, thereby expanding the HIV prevention workforce.

COURSES

 







THE HIV PCP NATIONAL ONLINE DIRECTORY

Providers who complete all five modules will receive the HIV PCP designation, and be automatically added to the national online directory. This directory is available for clients to locate providers who have demonstrated proficiency in HIV prevention.”

CONTACT

If you have any trouble accessing the online platform or have questions, contact info@healthhiv.org or call 202.232.6749.

ACTIVITY DESCRIPTION

The HIV PCP is a CME/CE multi-module educational certification program that will prepare providers to utilize the most individualized and up-to-date methods to prevent HIV infection. Upon completion of the self-paced program, providers will earn a HIV PCP certificate. The HIV PCP certification demonstrates competency in interdisciplinary, multi-level strategies for HIV prevention.

Participants who complete the certificate program will have an understanding of: the foundation of HIV epidemiology and policy in the United States, the provider’s role in identifying HIV risk and new cases, high impact strategies to prevent HIV through status-neutral-navigation, clinical guidelines to implement PrEP, and a framework of cultural humility that improves clients’ access to and retention in care.

Media: Enduring Material
Release and Expiration Dates: October 16, 2019 – October 15, 2020
Time to Complete: 60 minutes for each Module

Module Universal
Activity
Number

Educational Objective:
Upon completion of this activity, participants should be better able to:

Faculty Disclosures
Module 1:
HIV Prevention: Epidemiology
0468-9999-19-013-H01-P
  • Explain the history and epidemiology of HIV
    in the United States
  • Describe current policies regarding
    treatment for and prevention of HIV/AIDS
  • Identify strategies for HIV prevention
    and intervention
  • Discuss the economics of HIV
  • Describe the role of the HIV Prevention certification

Elizabeth Gregg, FNP-C, does not have any relevant
financial relationships with commercial interests.

Elizabeth Gregg, FNP-C, does not intend to discuss any
non-FDA-approved or investigational use of any
products/devices.

Jonathan Appelbaum, MD, has a financial interest/relationship
or affiliation in the form of:
Advisory Board with ViiV Healthcare and Merck.

Jonathan Appelbaum, MD, does not intend to discuss any
non-FDA-approved or investigational use of any products/devices.

Module 2:
HIV Testing and Assessing Risk
for Short Behavioral Intervention and Referral
0468-9999-19-014-H01-P
  • Describe screening for and diagnosis of HIV Infection
  • Explain how to identify HIV risk
  • Identify appropriate short behavioral interventions
  • Describe the importance of leveraging clinic and community partners

Elizabeth Gregg, FNP-C, does not have any
relevant financial relationships with commercial interests.

Elizabeth Gregg, FNP-C, does not intend to discuss any
non-FDA-approved or investigational use of any
products/devices.

Christopher Hucks-Ortiz, MPH, does not have any relevant financial relationships with commercial interests.

Christopher Hucks-Ortiz, MPH, does not intend to discuss
any non-FDA-approved or investigational use of any
products/devices.

Jonathan Appelbaum, MD, has a financial
interest/relationship or affiliation in the form of: 
Advisory Board with ViiV Healthcare and Merck.

Jonathan Appelbaum, MD, does not intend to discuss any
non-FDA-approved or investigational use of any products/devices.

Module 3:
Maintaining Serostatus
Negative and Viral Suppression: Preventing HIV Acquisition and Transmission
0468-9999-19-015-H01-P
  • Explain how to prevent HIV through post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP)
  • Describe the importance of sexually transmitted infection screening and treatment for HIV prevention
  • Describe the meaning of U=U and implications for HIV care

Stacy Kish does not have any relevant financial relationships with commercial interests.

Stacy Kish does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Jonathan Appelbaum, MD, has a financial interest/relationship or affiliation in the form of: Advisory Board with ViiV Healthcare and Merck.

Jonathan Appelbaum, MD, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

W. David Hardy, MD, has a financial interest/relationship or affiliation in the form of: Consulting with Enochian Biosciences, and  Advisory Board with Gilead Sciences, Merck, and ViiV Healthcare.

W. David Hardy, MD, does not intend to discuss any
non-FDA-approved or investigational use of any
Module 3: Maintaining Serostatus Negative and
Viral Suppression: Preventing HIV Acquisition and Transmission products/devices.

Module 4: Pre-Exposure Prophylaxis (PrEP) Clinical

0468-9999-19-016-H01-P

  • Describe the clinical basics of a pre-exposure prophylaxis intervention, including medication, adherence, and effectiveness.
  • Explain research findings supporting PrEP efficacy.
  • Discuss the Center for Disease Control and Prevention’s PrEP guidance including risk assessment, testing, PrEP prescription, PrEP coverage, and follow-up.
  • Describe emerging modalities for PrEP.

Richard Elion, MD, has a financial interest/relationship or affiliation in the form of:

Advisory panel, Speakers Bureau with Gilead and ViiV,and Speakers Bureau with Jannsen.

Richard Elion, MD, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Module 5: Enhancing Cultural Humility and Understanding Barriers to Care
0468-9999-19-017-H01-P
  • Describe the continuum of care engagement for HIV treatment and prevention
  • Discuss the role of stigma, discrimination, trauma, and social determinants of health in HIV risk
  • Explain cultural humility and the role it plays in providing HIV care and overcoming barriers to care
  • Describe trauma-informed care and its importance in HIV treatment and prevention
  • Introduce resources to mitigate financial barriers for clients

Emma Nace, FNP does not have any relevant financial relationships with commercial interests.

Emma Nace, FNP does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Christopher Hucks-Ortiz, MPH, does not have any relevant financial relationships with commercial interests.

Christopher Hucks-Ortiz, MPH, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

TARGET AUDIENCES

This activity is intended for Medical Doctors (MD), Doctors of Osteopathic Medicine (DO), Physician Assistants (PA), Nurse Practitioners (NP), Doctors of Pharmacy (PharmD), Registered Nurses (RN), Bachelors of Science in Nursing (BSN), and others.D, DO, PA, NP, PharmD, RN, BSN and others.

This activity is intended for primary care providers, HIV care providers and others providing or interested in providing HIV prevention services, including PrEP.

PROVIDERSHIP, CREDIT AND SUPPORT

This CME/MOC/CNE/CPE activity is jointly provided by the Medical Learning Institute, Inc., HealthHIV, and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Gilead Sciences, Inc.

 

PHYSICIAN CONTINUING MEDICAL EDUCATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Learning Institute, Inc., HealthHIV, and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC STATEMENT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

CONTINUING NURSING EDUCATION

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

CONTINUING PHARMACY EDUCATION

The Medical Learning Institute, Inc. (MLI) designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.  

UNIVERSAL ACTIVITY NUMBER

Module 1: 0468-9999-19-013-H01-P

Module 2: 0468-9999-19-014-H01-P

Module 3: 0468-9999-19-015-H01-P

Module 4: 0468-9999-19-016-H01-P

Module 5: 0468-9999-19-017-H01-P

TYPE OF ACTIVITY

Knowledge.

CONTENT REVIEW

The following Content Reviewers have nothing to disclose:

Kaushal Patel, MD

Bobbie Perrin, RN, OCN

Nancy Nesser, JD, PharmD

PLANNING COMMITTEE

Tracy L. Greene, MSN, RN, FNP-C, Lead Nursing Planner, MLI, has nothing to disclose.

Teresa Haile, RPh, MBA, Lead Pharmacy Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education and HealthHIV, joint providers, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this CME/MOC/CNE/CPE activity during the past 12 months unless listed below.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/CNE/CPE credit. Statements of Credit are awarded upon completion of the evaluation and request for credit at the end of the post-test and evaluation form.

CME: In order to receive a Statement of Credit, you must complete the evaluation form.

MOC: In order to receive MOC credit, completion of all post-test questions are required and a score of 70% or higher is needed to obtain MOC credit. Your ABIM number & DOB (MM/DD) are required as well.

CNE: In order to receive nurse credit, completion of all post-test questions are required. A score of 70% or higher is needed to obtain CNE credit.

CPE: In order to receive pharmacy credit, all evaluation questions are required as well as a valid NABP eProfile ID and DOB (MM/DD).

For pharmacists, Medical Learning Institute, Inc. will accept your completed evaluation form up to 30 days following participation and will report your participation in this educational activity to the NABP only if you provide your NABP e-profile number and date of birth. Within 6 weeks of participation, you will receive a confirmation email and can then view your participation record at the NABP website: mycpemonitor.net.

To receive the appropriate certificate, complete the evaluation at the end of the module. When you complete the evaluation, you will be provided with the certificate. It will also be emailed to the email address with which you registered.